Hepatitis C Combination Therapy - FDA gives Fast Track status to Vertex s Hepatitis C treatment

FDA gives Fast Track status to Vertex s Hepatitis C treatment
Mass High Tech - The U.S. Food and Drug Administration has granted Fast Track designation to VX-950, an investigational oral hepatitis C virus (HCV) treatment being developed by Vertex Pharmaceuticals Inc. According to Vertex officials, the FDA granted the Fast Track

XTL names CEO
Israel Business Arena - Ron Bentsur will replace chairman CEO Michael Weiss, who has served as acting CEO since February. Hadass Geyfman 11 Dec 05 17:36 Sources inform ''Globes'' that XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ); LSE: XTL ; TASE: XTL ) has appointed Ron

What's New in Hepatitis C: Current State of the Field and Future
Medscape News - The current standard of care for the treatment of previously untreated patients with chronic hepatitis C is a combination of once-weekly injection of pegylated interferon plus daily oral ribavirin. The treatment duration is dependent on HCV genotype

HGS to spin off gene research
Baltimore Sun - Human Genome Sciences Inc. said yesterday that it would spin off its CoGenesys division as an independent company that will focus on the early development of the Rockville biotech's gene-based research and leave the commercialization of later-stage

Diazyme Receives FDA 510(K) Approval for Enzymatic Total Bile Acids
Market Wire - SAN DIEGO, CA -- (MARKET WIRE) -- 12/22/2005 -- Diazyme Laboratories, a company that applies its proprietary enzyme technologies to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S